
iBio (IBIO) Stock Forecast & Price Target
iBio (IBIO) Analyst Ratings
Bulls say
iBio is developing an intriguing pipeline of novel antibody based therapeutics, with a focus on precision treatment for obesity and cardiometabolic diseases, supported by promising preclinical data, favorable half-life projections, and potential market exclusivity through orphan drug designations. However, the Company faces significant competition and risks associated with IP infringement and clinical trials, which could impact performance and the valuation of the stock.
Bears say
iBio is a preclinical stage biotechnology company utilizing AI technology for the development of antibodies, but faces challenges such as potential legal fees, competition, and need for more funds as they have not yet generated revenue and have a high burn rate. There are also risks associated with their clinical stage and patents.
This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.
iBio (IBIO) Analyst Forecast & Price Prediction
Start investing in iBio (IBIO)
Order type
Buy in
Order amount
Est. shares
0 shares